Opsona awarded €5.9m European FP7 grant
The European Commission has awarded Opsona Therapeutics €5.9 million to lead a European Framework 7 (FP7) consortium of research and clinical groups (termed MABSOT) in the advancement of clinical trials for its lead drug candidate OPN-305 in solid organ transplantation.
The specific focus of the consortium is the development of OPN-305 as a therapeutic agent for the prevention of Delayed Graft Function (DGF), a serious complication of the immediate postoperative period in renal transplantation. OPN-305 is a monoclonal antibody inhibitor of Toll-like receptor 2 (TLR-2).
Data generated by Opsona, its collaborators and independent scientists has provided solid scientific evidence for a link between TLR-2 and DGF. The consequences of DGF can be prolonged hospitalisation of patients, additional invasive procedures and transplant rejection. There is currently no specific therapeutic treatment for DGF.
Following the successful completion of a Phase I trial in 2011, the consortium plans to conduct a prospective randomised placebo-controlled Phase II trial in the prevention of DGF to be initiated in 2012.
Opsona received the award in December 2010 under the European Commission Seventh Framework Programme. The other members of the MABSOT ( Monoclonal Antibody Solid Organ Transplantation) consortium are:
- King's College London (UK) (www.kcl.ac.uk)
- Katholieke Universiteit Leuven (Belgium) (www.kuleuven.be)
- Institut Catala de Salut-Hospital Universitari de Bellvitge (http://www.bellvitgehospital.cat/)
- Academisch Ziekenhuis Groningen (Netherlands) (www.umcg.nl)
- Institutu Klinické a Experimentální Medicíny (Czech Republic) (www.ikem.cz)
- University of Newcastle upon Tyne (UK) (www.ncl.ac.uk)
- Euram Ltd (UK) (euram.ltd.uk)
- Almac Diagnostics Ltd (UK) (www.almacgroup.com)
For further information on the MABSOT consortium's objectives, visit the project's website.
EI Innovation Partnership
Opsona is partaking in an innovation partnership with Trinity College Dublin, the aim of this programme, which is co-funded by Enterprise Ireland and Opsona, is to assess the potential of Opsona’s TLR2 antibody as a novel therapeutic in Alzheimer’ disease (AD).
CSL Limited: 2009
Vaccine Adjuvant R&D collaboration with global specialty biopharmaceutical company CSL Limited.
Strategic Research Cluster with Merck, Trinity College Dublin and National University of Ireland (Maynooth). Objective: to identify New Stimulators of Three Classes of Receptors of Innate Immunity, TLRs, NLRs, and RLRs.
Wyeth Pharmaceuticals (a division of Pfizer): 2006
Discovery of New Chemical Entities and Biologics in the TLR space for the Treatment of Autoimmune and Inflammatory Diseases.